(NASDAQ: AARD) Aardvark Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.35%.
Aardvark Therapeutics's earnings in 2025 is N/A.On average, 4 Wall Street analysts forecast AARD's earnings for 2025 to be -$58,635,853, with the lowest AARD earnings forecast at -$64,656,741, and the highest AARD earnings forecast at -$46,865,289. On average, 4 Wall Street analysts forecast AARD's earnings for 2026 to be -$70,569,144, with the lowest AARD earnings forecast at -$83,099,100, and the highest AARD earnings forecast at -$59,883,425.
In 2027, AARD is forecast to generate -$62,487,052 in earnings, with the lowest earnings forecast at -$62,487,052 and the highest earnings forecast at -$62,487,052.